CDNA
HealthcareCareDx, Inc · Medical - Diagnostics & Research · $1B
What is CareDx, Inc?
CareDx is a small-cap healthcare company focused exclusively on the transplant care market. Founded in 2014 and headquartered in South San Francisco, it develops diagnostic tools and software that help clinicians monitor transplant patients after surgery.
CareDx generates revenue by selling molecular diagnostic tests and software platforms to transplant centers and caregivers worldwide. Its core technology uses donor-derived cell-free DNA to detect early signs of organ rejection in kidney, heart, and lung transplant recipients. The company also provides HLA typing solutions used in matching donors to recipients, and patient management software that helps transplant programs track outcomes and manage waitlists. Products are sold directly and through third-party distributors.
CareDx was founded in 2014 and is headquartered in South San Francisco, California.
- AlloSure — dd-cfDNA surveillance tests for kidney, heart, and lung transplants
- AlloMap Heart — gene expression monitoring for heart transplant patients
- TruSight HLA and AlloSeq — next-generation sequencing HLA typing solutions
- Ottr and XynQAPI — transplant patient management and waitlist tracking software
- AlloCare — mobile app supporting transplant recipients post-surgery
Is CDNA a Good Stock to Buy?
UQS Score rates CDNA as Below Average overall, reflecting meaningful challenges across several quality dimensions.
The Growth and Risk pillars both land at Neutral, suggesting CareDx is not in freefall — the business operates in a specialized niche with relatively stable demand from transplant centers. Valuation is also Neutral, meaning the market does not appear to be pricing in extreme optimism.
Both the Quality and Moat pillars score Weak, indicating the business has not yet demonstrated durable competitive advantages or the financial consistency investors typically seek in healthcare diagnostics companies.
See the exact pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CDNA pay dividends?
No — CareDx, Inc does not currently pay a dividend.
CareDx does not currently pay a dividend. As a small-cap diagnostics company still working to scale its transplant testing platform, the business prioritizes reinvesting available capital into product development, commercial expansion, and regulatory efforts rather than returning cash to shareholders.
When does CDNA report earnings?
CareDx reports earnings on a quarterly cadence, consistent with standard US-listed equity reporting schedules.
The company's recent results reflect a business navigating reimbursement dynamics and commercial scaling in the transplant diagnostics space. Revenue trends and profitability progress are key items investors watch each quarter.
For the most recent quarter's results and guidance, visit CareDx's investor relations page directly.
CDNA Price History
-74.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in CareDx, Inc?
Based on CareDx, Inc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CDNA Long-term Outlook
CareDx's Growth pillar at Neutral suggests the business is generating some forward momentum, though not at a pace that stands out within the broader healthcare diagnostics sector. The Neutral Risk profile indicates the company is not facing acute near-term threats, but the Weak Quality and Moat scores mean the path to durable profitability remains uncertain. Investors focused on long-term compounding may want to monitor whether the transplant testing platform can build pricing power and operating leverage over time.
Growth drivers
- Expanding adoption of dd-cfDNA surveillance testing across kidney, heart, and lung transplant programs
- Potential reimbursement coverage expansion for AlloSure and related diagnostic products
- Cross-sell opportunities between diagnostic tests and transplant management software platforms
Key risks
- Reimbursement uncertainty — payer coverage decisions can materially affect test volumes and revenue
- Weak Moat score signals limited pricing power against competing diagnostic and genomic testing providers
- Small-cap balance sheet constraints may limit the pace of commercial and R&D investment
CDNA vs Peers
CareDx competes in the specialized diagnostics and genomic testing space alongside several other small-cap healthcare companies.
OPKO operates across a broader set of diagnostics and pharmaceutical segments, giving it a different revenue mix compared to CareDx's transplant-focused model.
Castle Biosciences focuses on genomic testing for dermatologic and other cancers, targeting a different patient population than CareDx's transplant recipients.
Personalis applies advanced genomic sequencing to oncology and immunotherapy monitoring, competing in the broader liquid biopsy and cell-free DNA testing landscape.
Frequently Asked Questions
What does CareDx do?
CareDx develops and commercializes diagnostic tests and software for transplant patients. Its products help clinicians detect organ rejection early using donor-derived cell-free DNA technology, and it also provides HLA typing solutions and patient management platforms used by transplant centers worldwide.
Does CDNA pay dividends?
No, CareDx does not currently pay a dividend. The company reinvests its resources into expanding its transplant diagnostics portfolio and scaling its commercial operations rather than distributing cash to shareholders.
When does CDNA report earnings?
CareDx follows a standard quarterly earnings cadence for US-listed companies. For the exact timing of upcoming results, check the investor relations section of the CareDx website, where the company posts its earnings calendar.
Is CDNA a good stock to buy?
UQS Score rates CDNA as Below Average, driven by Weak scores in the Quality and Moat pillars. While Growth and Risk are Neutral, the overall profile suggests meaningful challenges remain. The complete pillar breakdown is available to UQS Pro members.
Is CDNA overvalued?
The UQS Valuation pillar for CDNA is rated Neutral, suggesting the market is not pricing in extreme optimism or pessimism relative to the company's fundamentals. View the full valuation metrics with a UQS Pro account.
How does CDNA compare to its competitors?
CareDx is narrowly focused on the transplant diagnostics market, which differentiates it from peers like OPKO Health, Castle Biosciences, and Personalis that serve broader or different patient populations. UQS Score provides side-by-side pillar comparisons for Pro members.
What is CDNA's market cap bracket?
CareDx is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded CareDx?
CareDx was established in 2014. Founding and leadership history is publicly available through the company's official website and SEC filings for investors who want to research the management team's background.
Is CDNA a long-term quality investment?
As a long-term quality indicator, CDNA's Below Average UQS Score — with Weak Quality and Moat pillars — signals that the business has not yet demonstrated the durable financial characteristics associated with high-quality compounders. Monitoring pillar trends over time is advisable.
What is the main competitive advantage of CareDx?
CareDx has built a specialized position in transplant diagnostics, particularly around donor-derived cell-free DNA testing. However, the UQS Moat pillar is rated Weak, suggesting this positioning has not yet translated into a clearly defensible competitive advantage by quantitative measures.
What sector does CDNA belong to?
CareDx operates in the Healthcare sector, specifically within the diagnostics and genomic testing segment. Its focus on post-transplant monitoring places it in a niche subsegment with distinct reimbursement and regulatory dynamics compared to broader diagnostics companies.
Is CDNA a growth stock or value stock?
Based on UQS pillar labels, CDNA shows a Neutral Growth profile and a Neutral Valuation, making it difficult to classify cleanly as either. It does not exhibit the strong growth trajectory of a high-growth stock, nor the deep discount characteristics of a classic value play.
Unlock Full CDNA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics behind each pillar
- ✓Compare CDNA side-by-side with sector peers
- ✓Track pillar changes across reporting periods
- ✓Screen for higher-quality alternatives in Healthcare
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
CDNA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 47.8 | 28.7 | 34.0 | 56.3 | 82.4 | 56.7 | 0.0 |
| May 22, 2026 | 47.8 | 28.7 | 34.0 | 56.3 | 82.4 | 56.9 | -0.1 |
| May 21, 2026 | 47.9 | 28.7 | 34.0 | 56.3 | 82.4 | 57.5 | -0.1 |
| May 19, 2026 | 48.0 | 28.7 | 34.0 | 56.3 | 82.4 | 58.3 | -0.2 |
| May 16, 2026 | 48.2 | 28.7 | 34.0 | 56.3 | 82.4 | 59.2 | +0.2 |
| May 15, 2026 | 48.0 | 28.7 | 34.0 | 56.3 | 82.4 | 58.4 | 0.0 |
| May 14, 2026 | 48.0 | 28.7 | 34.0 | 56.3 | 82.4 | 58.3 | +0.2 |
| May 13, 2026 | 47.8 | 28.7 | 34.0 | 56.3 | 82.4 | 57.0 | 0.0 |
| May 12, 2026 | 47.8 | 28.7 | 34.0 | 56.3 | 82.4 | 56.9 | 0.0 |
| May 11, 2026 | 47.8 | 28.7 | 34.0 | 56.3 | 82.4 | 56.5 | +3.9 |
CDNA — Pillar Breakdown
Quality
— 28.7/100 (25%)CareDx, Inc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 56.3/100 (20%)CareDx, Inc demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)CareDx, Inc carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 56.7/100 (15%)CareDx, Inc trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 34/100 (25%)CareDx, Inc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CDNA.
Score Composition
Financial Data
More Stock Analysis
How is the CDNA UQS Score Calculated?
The UQS (Unified Quality Score) for CareDx, Inc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses CareDx, Inc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether CareDx, Inc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.